<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02577848</url>
  </required_header>
  <id_info>
    <org_study_id>GLP-1-301xnk</org_study_id>
    <nct_id>NCT02577848</nct_id>
  </id_info>
  <brief_title>GLP-1 on Non-ST-Segment Elevation Myocardial Infarction</brief_title>
  <official_title>Effects of Liraglutide on Left Ventricular Function in Patients With Non-ST-Segment Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators planned to evaluate the effects of liraglutide on left ventricular function
      in patients with non-ST-segment elevation myocardial infarction (NSTEMI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with non-ST-segment elevation myocardial infarction (NSTEMI) are a heterogeneous
      group with respect to the risk of having a major adverse cardiac event (MACE). Elevation of
      blood glucose is a common metabolic disorder among patients with acute myocardial infarction
      (AMI) and is associated with adverse prognosis. Glucagon-like peptide-1 (GLP-1) is an
      incretin hormone that regulates plasma glucose. GLP-1 analogues have significant
      cardiovascular protective effects in patients with AMI. GLP-1 may have antioxidant and
      anti-inflammatory properties, and protect endothelial function. Studies in conscious,
      chronically instrumented dogs demonstrated that GLP-1 infusion increases insulin sensitivity
      and myocardial glucose uptake in postischemic contractile dysfunction and dilated
      cardiomyopathy. Liraglutide, a GLP-1 analogue, was reported to reduce cardiac rupture and
      infarct size and improve cardiac output in normal and diabetic mice. Continuous infusion of
      GLP-1 (1.5 pmol/kg/min) has been shown to improve functional recovery in patients with AMI
      complicated by decreased left ventricular function GLP-1 could protect against
      ischemia-reperfusion injury and improve cardiac function in patients with acute ST-segment
      elevation myocardial infarction. However, the effects of GLP-1 on NSTEMI patients remain
      unclear. The aim of this study was to evaluate the effects of liraglutide on left ventricular
      function in patients with NSTEMI.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>left ventricular ejection fractions</measure>
    <time_frame>at 3 months</time_frame>
    <description>The primary efficacy endpoint was the effect of liraglutide on left ventricular ejection fractions (LVEF) measured by transthoracic echocardiography at 3 months .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-minute walk distance</measure>
    <time_frame>at 3 months</time_frame>
    <description>The change in6-minute walk distance at 3 months after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment-emergent adverse events</measure>
    <time_frame>at 3 months</time_frame>
    <description>Treatment-emergent adverse events (TEAEs): hypoglycaemia, pancreatitis, thyroid cancer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>GLP-1 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1</intervention_name>
    <description>GLP-1 were taken daily for 7 days</description>
    <arm_group_label>GLP-1 group</arm_group_label>
    <other_name>Liraglutide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo were taken daily for 7 days</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        non-ST-segment elevation myocardial infarction (NSTEMI )

        Exclusion Criteria:

          1. unconscious at presentation

          2. had ST-segment elevation acute myocardial infarction

          3. NSTEMI requiring emergency percutaneous coronary angiography

          4. valvular heart disease

          5. cardiogenic shock

          6. hypoglycaemia

          7. diabetic ketoacidosis

          8. had a history of myocardial infarction

          9. stent implantation

         10. renal insufficiency

         11. had previously undergone coronary artery bypass surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhu Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>World Health Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Ren Chen, M.D.</last_name>
    <phone>+8610-66876231</phone>
    <email>chen_weiren@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Shi, M.D.</last_name>
      <phone>+8610-66876231</phone>
      <email>ggyyong@sina.com</email>
    </contact>
    <investigator>
      <last_name>Yu Tang Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, ten Berg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J, Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E, Widimsky P; ACCOAST Investigators. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013 Sep 12;369(11):999-1010. doi: 10.1056/NEJMoa1308075. Epub 2013 Sep 1.</citation>
    <PMID>23991622</PMID>
  </reference>
  <reference>
    <citation>Aronson D, Hammerman H, Kapeliovich MR, Suleiman A, Agmon Y, Beyar R, Markiewicz W, Suleiman M. Fasting glucose in acute myocardial infarction: incremental value for long-term mortality and relationship with left ventricular systolic function. Diabetes Care. 2007 Apr;30(4):960-6.</citation>
    <PMID>17392556</PMID>
  </reference>
  <reference>
    <citation>Lønborg J, Vejlstrup N, Kelbæk H, Bøtker HE, Kim WY, Mathiasen AB, Jørgensen E, Helqvist S, Saunamäki K, Clemmensen P, Holmvang L, Thuesen L, Krusell LR, Jensen JS, Køber L, Treiman M, Holst JJ, Engstrøm T. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012 Jun;33(12):1491-9. doi: 10.1093/eurheartj/ehr309. Epub 2011 Sep 14.</citation>
    <PMID>21920963</PMID>
  </reference>
  <reference>
    <citation>Ceriello A, Novials A, Ortega E, Canivell S, La Sala L, Pujadas G, Esposito K, Giugliano D, Genovese S. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care. 2013 Aug;36(8):2346-50. doi: 10.2337/dc12-2469. Epub 2013 Apr 5.</citation>
    <PMID>23564922</PMID>
  </reference>
  <reference>
    <citation>Nikolaidis LA, Doverspike A, Hentosz T, Zourelias L, Shen YT, Elahi D, Shannon RP. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther. 2005 Jan;312(1):303-8. Epub 2004 Sep 8.</citation>
    <PMID>15356213</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2015</study_first_posted>
  <last_update_submitted>October 16, 2015</last_update_submitted>
  <last_update_submitted_qc>October 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Chen Wei Ren, MD</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>Glucagon-like peptide-1</keyword>
  <keyword>Non-ST-segment elevation myocardial infarction</keyword>
  <keyword>Left ventricular ejection fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

